Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Early Outcomes of COVID-19 Lung Transplantation Recipients in Korea: A Single-Center Study

  • Shi A Kim (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jae Kwang Yun (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Geun Dong Lee (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Dong Kwan Kim (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Sehoon Choi (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2022.07.11
  • Accepted : 2022.10.23
  • Published : 2023.01.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Coronavirus disease 2019 (COVID-19) has been found to cause life-threatening respiratory failure, which can progress to irreversible lung damage. Lung transplantation can be a life-saving treatment in patients with terminal lung disease (e.g., acute respiratory distress syndrome caused by infection). This study aimed to present the clinical course and results after initial lung transplantation in patients with severe COVID-19 who did not recover even with optimal medical care. Methods: From August 2019 to February 2022, this study enrolled 10 patients with COVID-19 (5 men; median age, 55.7 years) who underwent lung transplantation at a single center in Korea. All patients' characteristics, clinical pathway, overall survival, complications, and operative data were collected and analyzed. Results: Veno-venous extracorporeal membrane oxygenation or an oxygenator in a right ventricular assist device circuit was applied to 90% of the patients, and the median length of extracorporeal life support before operation was 48.5 days. There were no cases of mortality after a median follow-up of 372.8 days (interquartile range, 262.25-489 days). The major complications included the requirement for postoperative extracorporeal membrane oxygenation support in 2 cases (20%), re-transplantation in 1 case (10%), and re-exploration due to bleeding in 2 cases (20%). During the follow-up period, 3 out of 10 patients died. Conclusion: Excellent early outcomes were observed for patients who underwent lung transplantation. Thus, lung transplantation can be an effective and feasible treatment for patients with end-stage lung disease caused by COVID-19.

Keywords

References

  1. Hawkins RB, Mehaffey JH, Charles EJ, Mannem HC, Roeser M. Lung transplantation for severe post-coronavirus disease 2019 respiratory failure. Transplantation 2021;105:1381-7. https://doi.org/10.1097/TP.0000000000003706
  2. Johns Hopkins University & Medicine. Johns Hopkins Coronavirus Resource Center [Internet]. Baltimore (MD): Johns Hopkins University & Medicine; 2020 [cited 2022 Apr 30]. Available from: https://coronavirus.jhu.edu/map.html.
  3. Bharat A, Machuca TN, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med 2021;9:487-97. https://doi.org/10.1016/S2213-2600(21)00077-1
  4. Kamp JC, Hinrichs JB, Fuge J, Ewen R, Gottlieb J. COVID-19 in lung transplant recipients: risk prediction and outcomes. PLoS One 2021;16:e0257807. https://doi.org/10.1371/journal.pone.0257807
  5. Lang C, Jaksch P, Hoda MA, et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. Lancet Respir Med 2020;8:1057-60. https://doi.org/10.1016/S2213-2600(20)30361-1
  6. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg 2020;155:990-2. https://doi.org/10.1001/jamasurg.2020.3950
  7. Chen JY, Qiao K, Liu F, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J (Engl) 2020;133:1390-6. https://doi.org/10.1097/CM9.0000000000000839
  8. Roach A, Chikwe J, Catarino P, et al. Lung transplantation for COVID-19-related respiratory failure in the United States. N Engl J Med 2022;386:1187-8. https://doi.org/10.1056/NEJMc2117024
  9. Saez-Gimenez B, Berastegui C, Barrecheguren M, et al. COVID-19 in lung transplant recipients: a multicenter study. Am J Transplant 2021;21:1816-24. https://doi.org/10.1111/ajt.16364
  10. Ko RE, Oh DK, Choi SM, et al. Lung transplantation for severe COVID19-related ARDS. Ther Adv Respir Dis 2022;16:17534666221081035. https://doi.org/10.1177/17534666221081035
  11. Bharat A, Querrey M, Markov NS, et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med 2020;12:eabe4282. https://doi.org/10.1126/scitranslmed.abe4282
  12. Oh DK, Hong SB, Kim HC, et al. Experience of international air transportation and subsequent lung transplant in a patient with COVID-19-associated acute respiratory distress syndrome: a case report. J Korean Med Sci 2021;36:e123. https://doi.org/10.3346/jkms.2021.36.e123
  13. King CS, Mannem H, Kukreja J, et al. Lung transplantation for patients with COVID-19. Chest 2022;161:169-78. https://doi.org/10.1016/j.chest.2021.08.041
  14. Messika J, Eloy P, Roux A, et al. COVID-19 in lung transplant recipients. Transplantation 2021;105:177-86. https://doi.org/10.1097/TP.0000000000003508
  15. Hoetzenecker K, Donahoe L, Yeung JC, et al. Extracorporeal life support as a bridge to lung transplantation-experience of a high-volume transplant center. J Thorac Cardiovasc Surg 2018;155:1316-28. https://doi.org/10.1016/j.jtcvs.2017.09.161
  16. Chang Y, Lee SO, Shim TS, et al. Lung transplantation as a therapeutic option in acute respiratory distress syndrome. Transplantation 2018;102:829-37. https://doi.org/10.1097/TP.0000000000002004